Navigation Links
Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
Date:6/2/2008

label study is to assess overall tumor response rate, and the study may be expanded to a total of 46 subjects following complete evaluation of data from the first 15 patients.

"Bavituximab represents a completely novel approach to treating cancer that helps mobilize the body's own immune system to attack tumors and the blood vessels supporting tumor growth and spread," said Dr. Raghunadharao Digumarti, professor of medical oncology at the Nizams Institute of Medical Sciences in Hyderabad, India, and a principal investigator of the Phase I clinical trial presented at ASCO. "We believe these encouraging study results support the upcoming Phase II safety and efficacy trials of bavituximab in breast and lung cancers that we look forward to participating in."

The open label, multi-center Phase I study was conducted in patients with refractory advanced solid tumors. The study objectives were to assess the safety and tolerability of bavituximab and to characterize its pharmacokinetic profile when used in combination with standard chemotherapy. Patients received up to eight weekly doses of bavituximab in combination with docetaxel, gemcitabine or paclitaxel plus carboplatin.

"The opportunity to share the positive results of the Phase I clinical study at ASCO provides us with a great platform to inform the broader oncology community about the potential of bavituximab and our anti-PS technology," said Steven W. King, president and CEO of Peregrine. "The promising anti-tumor activity of bavituximab in combination with chemotherapy seen in the Phase I and Phase II studies to date are encouraging, and we look forward to reporting additional results in the coming months."

Bavituximab is a monoclonal antibody that binds to the cellular membrane component PS that is usually located inside cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. By binding t
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
2. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
3. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
4. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
5. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
6. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
9. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
10. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
11. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... A major challenge before new biotechnology start-up ... of Boston-Cambridge, is gaining visibility that can lead to ... Director of Boston’s Adult Stem Cell Technology Center, LLC ... of his company an important priority since he started ... a social media marketing campaign launched earlier ...
(Date:8/28/2014)... 28, 2014 “This kit has an improved ... from 0 to 150 ppb,” said Mark Tess, PhD, Mycotoxin ... benefit to plant owners and USDA-GIPSA inspection agencies that have ... Testing can take place in a matter of minutes with ... plant test the feed and grain before accepting it, but ...
(Date:8/28/2014)... executives from clinical trial marketing firm BBK Worldwide will lead ... Clinical Trials 2014 , to be held at the Hyatt ... Patient recruitment experts Bonnie A. Brescia , Matthew ... on the benefits of employing an effective patient engagement strategy, ... mobile apps – can be used to drive study participation ...
(Date:8/28/2014)... BELLINGHAM, Washington, USA (PRWEB) August 27, 2014 ... Colorado next month for SPIE Laser Damage 2014 ... on optical materials for high-power lasers will run 14-17 ... international society for optics and photonics . , The ... key for understanding laser damage to optical materials will ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4BBK Worldwide Leads Sessions at Key September Events 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3
... OREX ), a biopharmaceutical company focused on the treatment of obesity, today ... Bank of America and Merrill Lynch 2009 Health ... 12, 2009, Time: 2:40 p.m. - 3:10 p.m. ... Speaker: Michael Narachi, Chief Executive Officer, , ...
... PharmAthene, Inc. (NYSE Amex: PIP ) ... chemical threats, announced a date change for its first ... financial results will now be released on Friday, May ... to discuss its first quarter 2009 financial results. ...
... DNDN ) announced today the pricing of an underwritten public ... Bank Securities will act as sole manager for the offering. ... option to purchase an additional 1,279,166 shares of common stock ... the net proceeds of the offering to develop manufacturing facilities, ...
Cached Biology Technology:Dendreon Announces Common Stock Offering 2
(Date:8/28/2014)... to Research Careers) Program has announced the travel ... 27th Annual Mouse Molecular Genetics Conference from September ... California. These awards are meant to promote ... from underrepresented groups into the mainstream of the ... of young scientists at the Genetics Society of ...
(Date:8/28/2014)... , Aug. 28, 2014  Privacy Advocate and Senior ... Jennifer Lynch , joins the lineup of biometric and ... annual Biometrics UnPlugged Executive Summit in Tampa, ... Previously announced speakers include Steven Rahman, Director, Technology and ... Sector at Experian. The theme of this year,s event ...
(Date:8/28/2014)... Energy production systems are good examples of complex ... like a networkincluding water for cooling, transport to ... management. Every step in the network chain is ... all mutually dependent. A team of UK-based scientists ... previously explored. The findings have been published in ...
Breaking Biology News(10 mins):Biometrics UnPlugged Welcomes the Electronic Frontier Foundation's Jennifer Lynch to the Mobility at the Crossroads of Commerce and Privacy Summit 2Inter-dependent networks stress test 2
... Scientists are reporting an advance toward enabling more blood ... increases transfusion safety by better matching donors and recipients. ... determining a broader range of blood types appears in ... Christophe Marquette and colleagues explain that most blood ...
... (Geneva, Switzerland) The International AIDS Society (IAS) today ... programme, Creative and Novel Ideas in HIV Research (CNIHR). ... Institutes of Health (NIH) and the NIH-supported Centers for ... and new ideas from early stage investigators whose primary ...
... "living fossil" descendents of the first plants that colonized ... because of invasive pests and habitat loss, especially those ... Cycas micronesica published recently as the cover article ... characterization of these plants as relicts (leftovers of formerly ...
Cached Biology News:International AIDS Society announces inaugural recipients of innovative HIV research awards 2International AIDS Society announces inaugural recipients of innovative HIV research awards 3International AIDS Society announces inaugural recipients of innovative HIV research awards 4New research on rapidly-disappearing ancient plant offers hope for species recovery 2New research on rapidly-disappearing ancient plant offers hope for species recovery 3
Rat CNTF R alpha Affinity Purified Polyclonal Ab...
Human MFRP MAb (Clone 291218)...
Human RELT/TNFRSF19L Affinity Purified Polyclonal Ab...
... NOS activity by monitoring the conversion of ... simple, sensitive, and specific for NOS activity ... and purified enzyme preparations. The kit includes ... reactions. Radiolabeled arginine and NADPH are not ...
Biology Products: